Advertisement

Chemoembolization with Drug-Eluting Beads

  • Robert C.G. Martin
  • Stewart Carter
Chapter

Abstract

Primary hepatic carcinoma remains a relatively uncommon disease in North America and Western Europe (0.5–2.0% of all cancers) [1, 2]. However it remains a much larger fraction (20–40%) in developing countries and is the 5th–6th most common malignancy worldwide (approximately 5.6% of all cancers) [3, 4]. Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver (70–85%) with an estimated 500 thousand to 1 million new cases annually and an associated mortality of approximately 600,000 [3, 5]. Recent studies in the USA have shown that the incidence of HCC is increasing, most likely related to chronic HCV infection [6].

Keywords

Liver-directed therapy Chemoembolization Drug-eluting bead Doxorubicin Hepatocellular 

References

  1. 1.
    El Serag HB, Davila JA, Petersen NJ et al (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823PubMedGoogle Scholar
  2. 2.
    Davila JA, Morgan RO, Shaib Y et al (2004) Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127:1372–1380CrossRefPubMedGoogle Scholar
  3. 3.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  4. 4.
    Bosch FX, Ribes J, Cleries R et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211, vCrossRefPubMedGoogle Scholar
  5. 5.
    Srivatanakul P, Sriplung H, Deerasamee S (2004) Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 5:118–125PubMedGoogle Scholar
  6. 6.
    Ahmed F, Perz JF, Kwong S et al (2008) National trends and disparities in the incidence of hepatocellular carcinoma, 1998–2003. Prev Chronic Dis 5:A74PubMedGoogle Scholar
  7. 7.
    Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236CrossRefPubMedGoogle Scholar
  8. 8.
    Reuter NP, Woodall CE, Scoggins CR et al (2009) Radiofrequency Ablation vs. Resection for Hepatic Colorectal Metastasis: Therapeutically Equivalent? J Gastrointest Surg 13:486–491CrossRefPubMedGoogle Scholar
  9. 9.
    Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590CrossRefPubMedGoogle Scholar
  10. 10.
    Raoul JL, Guyader D, Bretagne JF et al (1994) Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35:1782–1787PubMedGoogle Scholar
  11. 11.
    Raoul JL, Guyader D, Bretagne JF et al (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156–1161PubMedGoogle Scholar
  12. 12.
    Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583CrossRefPubMedGoogle Scholar
  13. 13.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMedGoogle Scholar
  14. 14.
    Marelli L, Stigliano R, Triantos C et al (2006) Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 32:594–606CrossRefPubMedGoogle Scholar
  15. 15.
    Lewis AL, Taylor RR, Hall B et al (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17:1335–1343CrossRefPubMedGoogle Scholar
  16. 16.
    Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342CrossRefPubMedGoogle Scholar
  17. 17.
    Tang Y, Taylor RR, Gonzalez MV et al (2006) Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release 116:e55–e56CrossRefPubMedGoogle Scholar
  18. 18.
    Taylor RR, Tang Y, Gonzalez MV et al (2007) Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30:7–14CrossRefPubMedGoogle Scholar
  19. 19.
    Lewis AL, Gonzalez MV, Leppard SW et al (2007) Doxorubicin eluting beads – 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 18:1691–1699CrossRefPubMedGoogle Scholar
  20. 20.
    Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481CrossRefPubMedGoogle Scholar
  21. 21.
    Poon RT, Tso WK, Pang RW et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108CrossRefPubMedGoogle Scholar
  22. 22.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  23. 23.
    Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711CrossRefPubMedGoogle Scholar
  24. 24.
    Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430CrossRefPubMedGoogle Scholar
  25. 25.
    Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759CrossRefPubMedGoogle Scholar
  26. 26.
    Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476CrossRefPubMedGoogle Scholar
  27. 27.
    Lammer J (2009) Evidence for Drug-Eluting Bead, initial data release from a 212 patient international, multicentre, prospective randomised controlled trial of doxorubicin in the treatment of hepatocellular carcinoma by drug-eluting bead embolisation. 2008. Oral presentation, Plenary session, Cardiovascular and Interventional Radiological Society of Europe annual meeting, 15th Sept 2009 CopenhagenGoogle Scholar
  28. 28.
    Nicolini A, Crespi S, Martinetti L (2007) TAE vs precision TACE in patients in the transplant waiting list. Cardiovascular and Interventional Radiological Society of Europe October 18th 2007 MilanGoogle Scholar
  29. 29.
    Goffette P (2008) Drug-eluting beads in the management of hepatocellular carcinoma prior to liver transplantation. European Conference of Interventional Oncology, Florence, Italy, April 12, 2008.Google Scholar
  30. 30.
    Lencioni R, Crocetti L, Petruzzi P et al (2008) Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 49:217–222CrossRefPubMedGoogle Scholar
  31. 31.
    Malagari K (2008) Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC bead. Expert Rev Anticancer Ther 8:1643–1650CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Robert C.G. Martin
    • 1
  • Stewart Carter
    • 1
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Louisville School of MedicineLouisvilleUSA

Personalised recommendations